Can monoclonal antibody staining by 323/A3 and Ca1 of benign breast biopsies predict the development of breast cancer?
- PMID: 8418084
- PMCID: PMC12201299
- DOI: 10.1007/BF01229525
Can monoclonal antibody staining by 323/A3 and Ca1 of benign breast biopsies predict the development of breast cancer?
Abstract
Monoclonal antibodies (mAb) raised to Ca1 and 323/A3 proteins have been suggested as markers of the premalignant breast. To establish the validity of this hypothesis the immunohistochemical staining patterns of these mAb have been studied in two different groups of patients with benign breast disease. One group comprised patients with benign biopsies who later went on to develop breast cancer. The second group were patients with benign breast disease who have not developed breast cancer. The immunohistochemical staining patterns of the two groups were compared. The staining patterns between the groups, when ducto-lobular, apocrine metaplasia and fibroadenomatous tissue were analysed, was similar. This occurred both for Ca1 and 323/A3 mAb. We conclude that the antigens identified by these mAb will not enable prediction of cancer development.
References
-
- Ashall F, Brammell ME, Harris H (1982) A new marker for human cancer cells 1. The Ca antigen and the Ca1 antibody. Lancet II:1–6 - PubMed
-
- Ciocca DR, Adams DJ, Bjerke RJ et al. (1983) Monoclonal antibody storage conditions and concentration effects on immunohistochemical specificity. J Histochem Cytochem 31:691–696 - PubMed
-
- Cochran WG (1954) Some methods for strengthening the common Chi squared tests. Biometrics 10:417–451
-
- Courtney SP, Mansel RE (1991) Reproducibility in recording immunohistochemical staining patterns of breast epithelium. Surg Res Commun 11:225–232
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous